|
Market Data
Incyte Corporation
Incyte Corporation is a biopharmaceutical firm focused on discovering, developing, and commercializing innovative therapies for various medical conditions across the United States, Europe, Canada, and Japan. The company's marketed products include treatments for myelofibrosis, lymphoma, biliary tract cancer, chronic myeloid leukemia, Merkel cell carcinoma, atopic dermatitis, and chronic graft-versus-host disease. Incyte also has a robust pipeline of clinical-stage candidates targeting diseases such as ovarian cancer, solid tumors, hidradenitis suppurativa, vitiligo, and systemic immune disorders. Their products are distributed through specialty and retail pharmacies, hospital pharmacies, and wholesale channels. Originally incorporated in 1991 and headquartered in Wilmington, Delaware, Incyte leverages its research and development capabilities to address significant unmet medical needs.
INCY is currently trading at $92.49, giving Incyte Corporation a market cap of 19.47B and a P/E ratio of 15.1. Today's range spans $92.49–$97.94, with shares opening at $96.60 and moving down $5.33 (5.4%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 61/100.
Over the past year INCY has traded between $56.13 and $112.29 - the current price is +64.8% off the 52-week low and -17.6% from the high. 34 analysts cover the stock with a Hold consensus and a mean 12-month target of $105.77 (range $71.00–$135.00), implying upside of +14.4%.
Factor models are actively underweighting INCY: large-cap, Healthcare, 19.47B market cap, 32/100 (SELL), bullish sentiment (61/100). Price: $92.49 (in the middle of its 52-week range). (P/E: 15.1) Momentum and trend-following strategies reduce exposure when scores drop below the 32/100 threshold; quality factors recalibrate; low-vol strategies find better risk-adjusted alternatives elsewhere in the sector. Annual range: $56.13–$112.29. The systematic de-risking compounds the fundamental concern.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.38 | - | - |
| Q4'25 | $1.57 | $1.80 | +14.8% |
| Q3'25 | $1.64 | $2.26 | +38.0% |
| Q2'25 | $1.47 | $1.57 | +6.6% |
| Q1'25 | $1.03 | $1.16 | +12.3% |
| Q4'24 | $1.55 | $1.43 | -8.0% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.2B | - | - |
| Q4'25 | $1.3B | $1.5B | +20.5% |
| Q3'25 | - | $1.4B | - |
| Q2'25 | - | $1.2B | - |
| Q1'25 | - | $1.1B | - |
| Q4'24 | - | $1.2B | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).